Cargando…

Computationally guided high-throughput design of self-assembling drug nanoparticles

Nanoformulations of therapeutic drugs are transforming our ability to effectively deliver and treat a myriad of conditions. Often, however, they are complex to produce and exhibit low drug loading, except for nanoparticles formed via co-assembly of drugs and small molecular dyes, which display drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Reker, Daniel, Rybakova, Yulia, Kirtane, Ameya R., Cao, Ruonan, Yang, Jee Won, Navamajiti, Natsuda, Gardner, Apolonia, Zhang, Rosanna M., Esfandiary, Tina, L’Heureux, Johanna, von Erlach, Thomas, Smekalova, Elena M., Leboeuf, Dominique, Hess, Kaitlyn, Lopes, Aaron, Rogner, Jaimie, Collins, Joy, Tamang, Siddartha M., Ishida, Keiko, Chamberlain, Paul, Yun, DongSoo, Lytoon-Jean, Abigail, Soule, Christian K., Cheah, Jaime H., Hayward, Alison M., Langer, Robert, Traverso, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197729/
https://www.ncbi.nlm.nih.gov/pubmed/33767382
http://dx.doi.org/10.1038/s41565-021-00870-y
Descripción
Sumario:Nanoformulations of therapeutic drugs are transforming our ability to effectively deliver and treat a myriad of conditions. Often, however, they are complex to produce and exhibit low drug loading, except for nanoparticles formed via co-assembly of drugs and small molecular dyes, which display drug loading capacities of up to 95%. There is currently no understanding of which of the millions of small molecule combinations can result in the formation of these nanoparticles. Here, we report the integration of machine learning with high-throughput experimentation to enable the rapid and large-scale identification of such nanoformulations. We identified 100 self-assembling drug nanoparticles from 2.1 million pairings, each including one of 788 candidate drugs and one of 2686 approved excipients. We further characterized two nanoparticles, sorafenib-glycyrrhizin and terbinafine-taurocholic acid, both ex vivo and in vivo. We anticipate that our platform can accelerate the development of safer and more efficacious nanoformulations with high drug loading capacities for a wide range of therapeutics.